European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

On 18 September 2017, a marketing authorisation valid through the European Union (EU) was issued for midostaurin in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy and for patients in complete response followed by midostaurin single...

Full description

Bibliographic Details
Main Authors: Yang Yu, kyriaki Tzogani, Tomas Salmonson, Christian Gisselbrecht, Francesco Pignatti, Didier Meulendijks, Carla Herberts, Paula Hennik, Remy Verheijen, Torunn Wangen, Gro Dahlseng Håkonsen, Torny Kaasboll, Marianne Dalhus, Bjorg Bolstad
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/4/6/e000606.full

Internet

https://esmoopen.bmj.com/content/4/6/e000606.full

Similar Items